GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
C5122 (R)-SLV 319Summary: CB1 receptor antagonist -
B2240 OlanzapineTarget: 5-HT2 Receptors|D2 ReceptorsSummary: Antagonist of 5-HT2A and dopamine D2 receptors -
B1354 Bisoprolol fumarateSummary: Selective α-adrenergic blocker -
B7314 XACSummary: Adenosine receptor antagonist -
C4968 Arachidonoyl SerinolSummary: CB1 receptor agonist -
B2237 Eletriptan HBrSummary: selective 5-HT1B and 5-HT1D receptor agonist -
B1353 Betaxolol HClSummary: β1 adrenergic receptor blocker -
B7313 PSB 0788Summary: adenosine A2B receptor antagonist -
C4786 ML-191Summary: inhibitor of LPI-induced phosphorylation of ERK1/2 -
B2236 DesvenlafaxineTarget: 5-HT Transporters|Norepinephrine transportersSummary: serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor
